Evidence map›Paper›PMID 39825588›Full record

ArticleArtificial organs2025

Granulocyte and Monocyte Adsorption Therapy in Patients With Sepsis: A Feasibility Study.

Osamu Nishida, Tomoyuki Nakamura, Takaaki Nakada, Gaku Takahashi, Yoshiki Masuda, Hiroki Tsubouchi, Yasuyuki Kakihana, Yuichiro Sakamoto, Osamu Takasu, Hiroyuki Suzuki and 11 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Artificial organs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Osamu NishidaDepartment of Anesthesiology and Critical Care Medicine, Fujita Health University School of Medicine, Toyoake, Japan.
Tomoyuki NakamuraDepartment of Anesthesiology and Critical Care Medicine, Fujita Health University School of Medicine, Toyoake, Japan.ORCID https://orcid.org/0000-0002-8348-4092
Takaaki NakadaDepartment of Emergency and Critical Care Medicine, Chiba University, Chiba, Japan.ORCID https://orcid.org/0000-0002-4480-556X
Gaku TakahashiDepartment of Critical Care and Emergency, Iwate Prefectural Advanced Critical Care and Emergency Center, Iwate Medical University, Shiwa, Japan.
Yoshiki MasudaDepartment of Intensive Care Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan.
Hiroki TsubouchiDepartment of Anesthesiology and Intensive Care, Ichinomiyanishi Hospital, Ichinomiya, Japan.
Yasuyuki KakihanaDepartment of Emergency and Intensive Care Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
Yuichiro SakamotoDepartment of Emergency and Critical Care Medicine, Saga University, Saga, Saga, Japan.
Osamu TakasuDepartment of Emergency and Critical Care Medicine, Kurume University, Kurume, Japan.
Hiroyuki SuzukiAdvanced Medical Emergency Department and Critical Care Center, Japanese Red Cross Maebashi Hospital, Maebashi, Japan.
Koichi NakazawaDepartment of Anesthesiology, Tokyo Medical University, Shinjuku, Japan.
Iwao KobayashiCritical Care and Emergency Center, Japanese Red Cross Asahikawa Hospital, Asahikawa, Japan.
Kent DoiThe Department of Emergency and Critical Care Medicine, The University of Tokyo, Tokyo, Japan.
Sohta UchiyamaJapan Department of Anesthesiology and Intensive Care Medicine, Nishichita General Hospital, Tokai, Japan.
Nobuya KitamuraEmergency and Critical Care Center, Kimitsu Chuo Hospital, Kisaraz, Japan.
Toru KotaniDepartment of Intensive Care Medicine, Showa University School of Medicine, Shinagawa, Japan.ORCID https://orcid.org/0000-0001-9504-0061
Naohide KuriyamaDepartment of Anesthesiology and Critical Care Medicine, Fujita Health University School of Medicine, Toyoake, Japan.
Noriyuki HattoriDepartment of Emergency and Critical Care Medicine, Chiba University, Chiba, Japan.
Yasushi SuzukiDepartment of Critical Care and Emergency, Iwate Prefectural Advanced Critical Care and Emergency Center, Iwate Medical University, Shiwa, Japan.ORCID https://orcid.org/0000-0002-6142-5657
Hiroomi TatsumiDepartment of Intensive Care Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan.
Kazuhiro MoriyamaLaboratory for Immune Response and Regulatory Medicine, Fujita Health University School of Medicine, Toyoake, Japan.ORCID https://orcid.org/0000-0002-5598-6669

Funding

JIMRO CO. LTD
6 · The paper itself

Abstract

backgroundThe pathogenesis of sepsis is thought to be linked to a dysregulated immune response, particularly that involving neutrophils. We have developed a granulocyte adsorption column as a "decoy organ," which relocates the massive inflammation in organs in the body to a blood purification column. This study was conducted to assess the safety and experimental effectiveness of granulocyte monocyte adsorption apheresis-direct hemoperfusion (G1-DHP) in the treatment of patients with sepsis, using a prospective, multicenter design.

methodsThe study included patients diagnosed with sepsis and with an APACHE II score ranging from 17 to 34. A total of five G1-DHP were performed within 3 days of patient enrollment. The primary endpoint was the change in sequential organ failure assessment (SOFA) score from enrollment to 7 days, and the safety endpoints were adverse events and mortality at 28 days.

resultsG1-DHP was performed on 82 patients. The median (interquartile range) SOFA score decreased from 10 (8-11) to 4 (3-7) after 7 days (n = 70; p < 0.01). Granulocytes, mainly neutrophils, were adsorbed, and the neutrophil-to-lymphocyte ratio significantly improved (p < 0.01). Notable improvements were observed in the SOFA scores for circulation and renal function. The acute physiology and chronic health evaluation II score of the 77 patients evaluated for mortality was 27, and the 28-day mortality rate was 7.8%.

conclusionsThis study confirmed that G1-DHP can be safely used as an adjunct to standard sepsis treatment regimens. Although further investigations are required, G1-DHP is a promising supplemental therapy for sepsis.

trial registrationjRCT1080225183 (Japan Registry of Clinical Trials identifier).

Indexed as

GranulocytesHemoperfusionMonocytesSepsisAdsorptionAgedAPACHEFeasibility StudiesFemaleHumansMaleMiddle AgedOrgan Dysfunction ScoresProspective StudiesTreatment Outcomeadacolumncytokinehemoadsorptionneutrophilssepsissequential organ failure assessment

Identifiers

PMID39825588
PMCPMC12019104

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.